Are dacomitinib and dacomitinib the same drug?

Dacomitinib(Dacomitinib) and dacomitinib are actually the same drug, but differences in Chinese translation lead to differences in names. Their English names are Dacomitinib, which is an oral targeted therapy drug used to treat non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. Since there may be different choices of "ke" and "gram" in the transliteration process of Chinese drug names, the two names "dacomitinib" and "dacomitinib" are often interchangeable on the Internet, in clinical use, and in patient communication. Although they sound different, the chemical composition, pharmacological effects, clinical indications and usage methods they point to are exactly the same. Patients only need to pay attention to its English name "Dacomitinib" when receiving treatment or querying information to confirm.

Dacomitinib is an irreversible second-generationEGFR tyrosine kinase inhibitor (TKI), mainly suitable for the first-line treatment of patients with metastatic non-small cell lung cancer who have sensitive mutations in the EGFR gene (such as exon 19 deletions or L858R point mutations). Clinical studies have shown that dacomitinib has obvious advantages over first-generation EGFR-TKIs (such as gefitinib) in prolonging patients' progression-free survival and overall survival. However, it is also more likely to cause adverse reactions such as rash and diarrhea. Therefore, doctors usually adjust the dose according to individual tolerance when using this drug. When purchasing or using this drug, patients do not need to worry if they find that the drug packaging is labeled "Dacomitinib" or "Dacomitinib". There is no difference between the two.

In general, dacomitinib and dacomitinib are the same drug, only the Chinese naming is different. When checking information, communicating with doctors or searching online, patients only need to pay attention to the English name of the drug Dacomitinib to accurately identify and understand its therapeutic properties and avoid unnecessary confusion or misunderstanding due to name differences.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro